search
Back to results

Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old (PAED4)

Primary Purpose

Asthma in Children

Status
Completed
Phase
Phase 2
Locations
Denmark
Study Type
Interventional
Intervention
free comb. beclomethasone DPI and formoterol DPI
CHF 1535 50/6 NEXT DPI
Sponsored by
Chiesi Farmaceutici S.p.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma in Children focused on measuring asthma children NEXT DPI LABA ICS inhalation

Eligibility Criteria

5 Years - 11 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male/Female children aged 5 -11y
  2. Written informed consent obtained by parents/legal representative (according to local regulation) and by the minor (age and local regulation permitting).
  3. Children with stable asthma
  4. Children with asthma on regular treatment with ICS or using short-acting inhaled beta2-agonists as reliever to control asthma symptoms
  5. Forced expiratory volume in one second (FEV1) > 70% of predicted values (% pred) after withholding beta2-agonists treatment for a minimum of 4 h prior to each study treatment.
  6. A cooperative attitude and ability to be trained about the proper use of DPI and compliant to study procedures.

Exclusion Criteria:

  1. Past or present diagnoses of cardiovascular, renal or liver disease
  2. Known hypersensitivity to the active treatments
  3. Exacerbation of asthma symptoms within the previous 4 weeks
  4. Inability to perform the required breathing technique and blood sampling
  5. Hospitalization due to exacerbation of asthma within 1 month prior to screening (visit 1)
  6. Lower respiratory tract infection within 1 month prior to screening (visit 1)
  7. Disease (other than asthma) which might influence the outcome of the study
  8. Obesity, i.e. > 97% weight percentile by local standards

Sites / Locations

  • BørneAstmaKlinikken, Hans Knudsens Plads 1A,

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

reference treatment

CHF 1535 NEXT DPI

Arm Description

Free combination of Beclomethasone dipropionate DPI and Formoterol fumarate DPI

CHF 1535 50/6 NEXT DPI

Outcomes

Primary Outcome Measures

B17MP (active metabolite of BDP) Area Under Curve (AUC)
B17MP: Profile of Pharmacokinetics

Secondary Outcome Measures

B17MP Cmax,Tmax,T1/2
BDP: profile of pharmacokinetics.
BDP Area Under Curve (AUC), Cmax, Tmax, T1/2
BDP: profile of Pharmacokinetics
Formoterol Area Under Curve (AUC), Cmax, Tmax, T1/2
Formoterol: profile of pharmacokinetics
plasma potassium Area Under Curve (AUC), Cmin, Tmin
plasma potassium to evaluate drug systemic effect
Heart Rate: Time averaged Heart Rate value: AUC0-t/t
Heart Rate to evaluate drug systemic effect
Urinary Cortisol: Amount excreted in 0-8hours (Ae),8h cortisol urinary excretion normalized for 8h creatinine excretion (Ae/Aecreat).
Urinary cortisol to evaluate drug systemic effect

Full Information

First Posted
October 28, 2011
Last Updated
July 30, 2020
Sponsor
Chiesi Farmaceutici S.p.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT01468272
Brief Title
Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old
Acronym
PAED4
Official Title
A Single-dose,Open-label,Randomized,2-way Cross-over,Clinical Pharmacology Study of CHF1535 50/6 NEXT DPI® Fixed Combination of Beclomethasone Dipropionate 50µg Plus Formoterol Fumarate 6µg)Versus the Free Combination of Licensed Beclomethasone DPI and Formoterol DPI in Asthmatic Children
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
August 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chiesi Farmaceutici S.p.A.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a pharmacokinetic comparison of CHF 1535 50/6 NEXT DPI versus the free combination of Beclomethasone DPI and Formoterol DPI in children (5 to 11 years old) of a formulation already approved in adults.
Detailed Description
Pharmacokinetic study in asthmatic children 5 to 11 years old treated with either a fixed combination of beclomethasone 50 ug/unit dose plus formoterol fumarate 6 ug/unit dose via the NEXT DPI dry powder inhaler or a free combination of Beclomethasone 100 ug DPI and Formoterol 6 ug DPI according to a cross-over design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma in Children
Keywords
asthma children NEXT DPI LABA ICS inhalation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
reference treatment
Arm Type
Active Comparator
Arm Description
Free combination of Beclomethasone dipropionate DPI and Formoterol fumarate DPI
Arm Title
CHF 1535 NEXT DPI
Arm Type
Experimental
Arm Description
CHF 1535 50/6 NEXT DPI
Intervention Type
Drug
Intervention Name(s)
free comb. beclomethasone DPI and formoterol DPI
Intervention Description
free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
Intervention Type
Drug
Intervention Name(s)
CHF 1535 50/6 NEXT DPI
Intervention Description
four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
Primary Outcome Measure Information:
Title
B17MP (active metabolite of BDP) Area Under Curve (AUC)
Description
B17MP: Profile of Pharmacokinetics
Time Frame
predose, 15,30min, 1,2,4,6,8 hours post dose
Secondary Outcome Measure Information:
Title
B17MP Cmax,Tmax,T1/2
Description
BDP: profile of pharmacokinetics.
Time Frame
predose, 15min,30min,1,2,4,6,8 hours post dose
Title
BDP Area Under Curve (AUC), Cmax, Tmax, T1/2
Description
BDP: profile of Pharmacokinetics
Time Frame
predose, 15min,30min,1,2,4,6,8 hours postdose
Title
Formoterol Area Under Curve (AUC), Cmax, Tmax, T1/2
Description
Formoterol: profile of pharmacokinetics
Time Frame
predose, 15min, 30 min, 1,2,4,6,8 hours postdose
Title
plasma potassium Area Under Curve (AUC), Cmin, Tmin
Description
plasma potassium to evaluate drug systemic effect
Time Frame
predose, 15min, 30min, 1, 2, 4, 6, 8 hours postdose
Title
Heart Rate: Time averaged Heart Rate value: AUC0-t/t
Description
Heart Rate to evaluate drug systemic effect
Time Frame
predose, 15min, 30min, 1, 2, 4, 6, 8 hours postdose
Title
Urinary Cortisol: Amount excreted in 0-8hours (Ae),8h cortisol urinary excretion normalized for 8h creatinine excretion (Ae/Aecreat).
Description
Urinary cortisol to evaluate drug systemic effect
Time Frame
from predose up to 8 hours postdose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
11 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male/Female children aged 5 -11y Written informed consent obtained by parents/legal representative (according to local regulation) and by the minor (age and local regulation permitting). Children with stable asthma Children with asthma on regular treatment with ICS or using short-acting inhaled beta2-agonists as reliever to control asthma symptoms Forced expiratory volume in one second (FEV1) > 70% of predicted values (% pred) after withholding beta2-agonists treatment for a minimum of 4 h prior to each study treatment. A cooperative attitude and ability to be trained about the proper use of DPI and compliant to study procedures. Exclusion Criteria: Past or present diagnoses of cardiovascular, renal or liver disease Known hypersensitivity to the active treatments Exacerbation of asthma symptoms within the previous 4 weeks Inability to perform the required breathing technique and blood sampling Hospitalization due to exacerbation of asthma within 1 month prior to screening (visit 1) Lower respiratory tract infection within 1 month prior to screening (visit 1) Disease (other than asthma) which might influence the outcome of the study Obesity, i.e. > 97% weight percentile by local standards
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hans Bisgaard
Organizational Affiliation
BorneAstmaKlinikken, Copenaghen, Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
BørneAstmaKlinikken, Hans Knudsens Plads 1A,
City
Copenhagen,
ZIP/Postal Code
2100
Country
Denmark

12. IPD Sharing Statement

Citations:
PubMed Identifier
24993817
Citation
Chawes BL, Govoni M, Kreiner-Moller E, Vissing NH, Poorisrisak P, Mortensen L, Nilsson E, Bisgaard A, Dossing A, Deleuran M, Skytt NL, Samandari N, Piccinno A, Sergio F, Ciurlia G, Poli G, Acerbi D, Singh D, Bisgaard H. Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent. Respir Med. 2014 Aug;108(8):1108-16. doi: 10.1016/j.rmed.2014.05.007. Epub 2014 Jun 17.
Results Reference
result
Links:
URL
https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001208-36
Description
Study Record on EU Clinical Trials Register including results

Learn more about this trial

Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old

We'll reach out to this number within 24 hrs